StockNews.com upgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN – Free Report) from a buy rating to a strong-buy rating in a report published on Sunday morning. Separately, Cantor Fitzgerald ...
Atria Investments Inc bought a new position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) in the 4th quarter, HoldingsChannel.com reports. The fund bought 7,978 shares of the specialty ...
Today, we are looking at branded pharmaceuticals stocks, starting with Supernus Pharmaceuticals (NASDAQ:SUPN). The branded pharmaceutical industry relies on a high-cost, high-reward business model ...
Today, we are looking at branded pharmaceuticals stocks, starting with Supernus Pharmaceuticals (NASDAQ:SUPN). The branded pharmaceutical industry relies on a high-cost, high-reward business model, ...
NEW YORK, NY / ACCESS Newswire / March 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback